O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+32.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.99B
AUM Growth
+$4.99B
(+7.1%)
Cap. Flow
-$375M
Cap. Flow
% of AUM
-7.51%
Top 10 Holdings %
Top 10 Hldgs %
36.59%
Holding
136
New
14
Increased
17
Reduced
27
Closed
25
Top Buys
| 1 |
Eli Lilly
LLY
|
$105M |
| 2 |
Biogen
BIIB
|
$70.1M |
| 3 |
Elevance Health
ELV
|
$66.7M |
| 4 |
Scholar Rock
SRRK
|
$41.6M |
| 5 |
argenx
ARGX
|
$19.8M |
Top Sells
| 1 |
Humana
HUM
|
$106M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$85.3M |
| 3 |
Baxter International
BAX
|
$84.5M |
| 4 |
Cigna
CI
|
$66.2M |
| 5 |
AbbVie
ABBV
|
$49.2M |
Sector Composition
| 1 | Healthcare | 98.25% |
| 2 | Industrials | 1.02% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
scPharmaceuticals
SCPH
$296M
| $34.9M | 0.7% |
5,559,528
| – | – |
|
|
52
argenx
ARGX
$44.2B
| $32.2M | 0.64% |
84,600
+52,000
| +160% | +$19.8M |
|
|
FUSN
53
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $30M | 0.6% |
3,122,770
| – | – |
|
|
SLRN
54
DELISTED
ACELYRIN
SLRN
| $29.9M | 0.6% |
4,001,711
-1,324,591
| -25% | -$9.88M |
|
55
Neumora Therapeutics
NMRA
$283M
| $25.6M | 0.51% |
1,500,000
| – | – |
|
56
Xenon Pharmaceuticals
XENE
$2.99B
| $25.3M | 0.51% |
550,000
-408,793
| -43% | -$18.8M |
|
57
Rhythm Pharmaceuticals
RYTM
$6.75B
| $24.7M | 0.49% |
536,642
-47,000
| -8% | -$2.16M |
|
58
Repare Therapeutics
RPTX
$73.9M
| $24.3M | 0.48% |
3,322,488
| – | – |
|
59
AbCellera Biologics
ABCL
$1.19B
| $23.9M | 0.48% |
4,180,768
| – | – |
|
60
Vera Therapeutics
VERA
$1.47B
| $23.3M | 0.47% |
1,518,115
| – | – |
|
61
PMV Pharmaceuticals
PMVP
$82.1M
| $20.1M | 0.4% |
6,475,291
-87,786
| -1% | -$272K |
|
|
KNTE
62
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $19M | 0.38% |
8,009,729
| – | – |
|
63
TELA Bio
TELA
$65.4M
| $18.8M | 0.37% |
2,835,542
| – | – |
|
|
JBIO
64
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $17.1M | 0.34% |
756,930
| – | – |
|
65
Invivyd
IVVD
$218M
| $16.3M | 0.32% |
4,127,565
-1,142,835
| -22% | -$4.5M |
|
66
Immatics
IMTX
$662M
| $16.3M | 0.32% |
1,543,407
+493,207
| +47% | +$5.19M |
|
67
Adicet Bio
ACET
$60.8M
| $15.7M | 0.31% |
8,322,140
| – | – |
|
68
Alnylam Pharmaceuticals
ALNY
$58.6B
| $15.2M | 0.3% |
+79,400
| New | +$15.2M |
|
69
Krystal Biotech
KRYS
$4.35B
| $12.9M | 0.26% |
+103,700
| New | +$12.9M |
|
70
Verastem
VSTM
$585M
| $12.4M | 0.25% |
1,529,115
| – | – |
|
71
Corvus Pharmaceuticals
CRVS
$419M
| $12.2M | 0.24% |
6,943,654
| – | – |
|
72
Regeneron Pharmaceuticals
REGN
$59.8B
| $11.9M | 0.24% |
13,500
| – | – |
|
73
Amicus Therapeutics
FOLD
$2.42B
| $11.4M | 0.23% |
+806,000
| New | +$11.4M |
|
74
Passage Bio
PASG
$22.7M
| $10.2M | 0.2% |
10,124,576
| – | – |
|
75
Heron Therapeutics
HRTX
$204M
| $10.1M | 0.2% |
5,928,591
+5,125,891
| +639% | +$8.71M |
|